Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization

被引:80
作者
Jeuken, JWM
Sprenger, SHE
Wesseling, P
Macville, MVE
von Deimling, A
Teepen, HLJM
van Overbeeke, JJ
Boerman, RH
机构
[1] Univ Nijmegen Hosp, Dept Neurosurg 309, NL-6500 HB Nijmegen, Netherlands
[2] Univ Nijmegen Hosp, Dept Neurol, NL-6500 HB Nijmegen, Netherlands
[3] Univ Nijmegen Hosp, Dept Pathol, NL-6500 HB Nijmegen, Netherlands
[4] St Elizabeth Hosp, Dept Pathol, Tilburg, Netherlands
[5] Humbolt Univ Hosp, Dept Neuropathol, Berlin, Germany
关键词
1p; 7; 10; 19q; CGH; gliomas; oligodendroglial tumors;
D O I
10.1097/00005072-199906000-00005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In contrast to astrocytic tumors, approximately two thirds of anaplastic oligodendrogliomas are reported to be chemosensitive. Relatively little is known about the genetic aberrations in oligodendroglial tumors (OTs). In order to elucidate oligodendroglial oncogenesis and to find specific genetic aberrations that may have prognostic and therapeutic implications, we performed comparative genomic hybridization (CGH) to detect chromosomal copy number changes in 17 low-grade OTs (LG-OTs) and 12 high-grade OTs (HG-OTs) lacking a prominent astrocytic component. Loss of chromosome 1p (798) and 19q (76%) were most frequently detected by CGH, all LG-OTs and 50% of the HG-OTs contained -1p (including 1p36-32), -19q (including 19q13.3), or both, and the rest of the HG-OTs showed +7, -10, or both. Since losses of 1p36-32 and 19q13.3 were mutually exclusive with +7 or -10, the HG-OTs could be divided in -1p/-19q and +7/-10 tumors. While the -1p/-19q tumors can be considered as pure anaplastic oligodendrogliomas, the +7/-10 tumors may rather be glioblastomas with prominent oligodendroglial differentiation. We conclude that CGH is a powerful tool to assist in the identification of 2 major subgroups of HG-OTs with prognostic and possibly therapeutic relevance.
引用
收藏
页码:606 / 612
页数:7
相关论文
共 55 条
[1]   AN INTEGRATED METRIC PHYSICAL MAP OF HUMAN-CHROMOSOME-19 [J].
ASHWORTH, LK ;
BATZER, MA ;
BRANDRIFF, B ;
BRANSCOMB, E ;
DEJONG, P ;
GARCIA, E ;
GARNES, JA ;
GORDON, LA ;
LAMERDIN, JE ;
LENNON, G ;
MOHRENWEISER, H ;
OLSEN, AS ;
SLEZAK, T ;
CARRANO, AV .
NATURE GENETICS, 1995, 11 (04) :422-427
[2]   THE MOLECULAR-BIOLOGY OF BRAIN-TUMORS [J].
BARKER, FG ;
ISRAEL, MA .
NEUROLOGIC CLINICS, 1995, 13 (04) :701-&
[3]  
BELLO MJ, 1995, INT J CANCER, V64, P207
[4]   MOLECULAR ANALYSIS OF CHROMOSOME-1 ABNORMALITIES IN HUMAN GLIOMAS REVEALS FREQUENT LOSS OF 1P IN OLIGODENDROGLIAL TUMORS [J].
BELLO, MJ ;
VAQUERO, J ;
DECAMPOS, JM ;
KUSAK, ME ;
SARASA, JL ;
SAEZCASTRESANA, J ;
PESTANA, A ;
REY, JA .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (02) :172-175
[5]  
Bentz M, 1998, GENE CHROMOSOME CANC, V21, P172, DOI 10.1002/(SICI)1098-2264(199802)21:2<172::AID-GCC14>3.3.CO
[6]  
2-T
[7]   The glial and mesenchymal elements of gliosarcomas share similar genetic alterations [J].
Boerman, RH ;
Anderl, K ;
Herath, J ;
Borell, T ;
Johnson, N ;
SchaefferKlein, J ;
Kirchhof, A ;
Raap, AK ;
Scheithauer, BW ;
Jenkins, RB .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (09) :973-981
[8]  
Burger PC, 1994, TUMORS CENTRAL NERVO
[9]  
CAINCROSS JG, 1994, RECENT RESULTS CANC, V135, P127
[10]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479